

**Acentra Health/Hillsborough (HCHCP) Prior Authorization
*BiPAP Questionnaire***

**CPT CODES: E0470, E0471, E0472**

***Initial Rental Request:***

**Q1** Patient has daytime symptoms of sleep−disordered breathing

**Q2** Patient has obstructive sleep apnea and failed CPAP

**Q3** Patient has central/complex sleep apnea with Dx by attended facility−based polysomnogram

**Q4** Patient has central/complex sleep apnea and CPAP failed to improve daytime symptoms of sleep−disordered breathing

**Q5** Patient has central/complex sleep apnea with AHI improved with use of NIPPV

**Q6** Patient has progressive neuromuscular condition with PCO2 >= 45 mmHg measured on room air/O2 while awake

**Q7** Patient has progressive neuromuscular condition with FVC (Forced vital capacity) < 50% predicted

**Q8** Patient has progressive neuromuscular condition with Maximum inspiratory pressure < 60 cm H2O

**Q9** Patient has progressive neuromuscular condition with Nocturnal O2 sat <= 88% measured on room air/O2 for >= 5 mins

**Q10** Patient has COPD with PCO2 >= 55 mmHg measured on room air/O2 while awake

**Q11** Patient has COPD with PCO2 50 to 54 mmHg and nocturnal desaturation and evidenced by nocturnal O2 sat <= 88% and Measured on O2 >= 2L/min for >= 5 min

**Q12** Patient has COPD with PCO2 50 to 54 mmHg and hospitalization >= 2x w/in 1 yr for respiratory failure

**Q13** Patient has limited thoracic expansion with PCO2 >= 45 mmHg measured on room air/O2 while awake

**Q14** Patient has limited thoracic expansion with Nocturnal O2 sat <= 88% measured on room air/O2 for >= 5 mins

**Q15** A face-to-face clinical evaluation by the treating physician before the sleep test to assess the patient for OSA.

**Q16** A Medicare-covered sleep test that meets one of the following: The Apnea-Hypopnea Index (AHI) or Respiratory Disturbance Index (RDI) is greater than or equal to 15 events per hour with a minimum of 30 events; or

Revised July 2021 Page 1



The AHI or RDI is greater than or equal to 5 and less than or equal to 14 events per hour with a minimum of 10 events and documentation of: a. Excessive daytime sleepiness, impaired cognition, mood disorders, or insomnia; or

Hypertension, ischemic heart disease, or history of stroke.

**Q17** The patient and/or their caregiver received instructions from the supplier of the PAP device and accessories in the proper use and care of the equipment.

**Q18** A face-to-face encounter during the 6-month period preceding the written order.

**Q19** Objective evidence of continued need and continued use.

**Q20** The CPAP device has been tried and proved ineffective based on the therapeutic trial conducted either in a facility or in a home setting.

**Q21** The patient has had at least a 70% or higher compliance rate of using the CPAP machine

***Renewal Request***

Continued coverage of a PAP device ([0470 or [0601) beyond the first three months of therapy requires that, no sooner than the 31st day but no later than the 91st day after initiating therapy, the treating physician must conduct a clinical re-evaluation and document that the beneficiary is benefiting from PAP therapy.

For PAP devices with initial dates of service on or after November 1, 2008, documentation of clinical benefit is demonstrated by:

**Q22** Face-to-face clinical re-evaluation by the treating physician with documentation that symptoms of obstructive sleep apnea are improved; **and**,

**Q23** Objective evidence of adherence to use of the PAP device, reviewed by the treating physician.

**Q24** Adherence to therapy is defined as use of PAP ≥4 hours per night on 70% of nights during a consecutive thirty (30) day period anytime during the first three (3) months of initial usage.

If the above criteria are not met, continued coverage of a PAP device and related accessories will be **denied as not medically necessary**.

Beneficiaries who fail the initial 12 week trial are eligible to requalify for a PAP device but must have both:

1. Face-to-face clinical re-evaluation by the treating physician to determine the etiology of the failure to respond to PAP therapy; **and**,
2. Repeat sleep test in a facility-based setting (Type 1 study).

Revised July 2021 Page 2